Vertex Pharmaceuticals Incorporated (VRTX) dropped by -0.19 or -0.16 points during the last session to $85.71 per share. One of the highlights of the day was the net money flow figure, which stood at $1.99 million even as the stock accepted $2.61 million in upticks but rejected $0.63 million in downticks. The up/down ratio for the last observation was a 4.17. The 1-week percentage change for the stock price is registered at -1.9%.A block transaction occurred with $1.64 million in upticks and $0 million in downticks while the up/down ratio was calculated to be 0. The stock witnessed a net inflow of $1.64 million at the end of the block trade.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Vertex Pharmaceuticals Incorporated rose by 1.23% in the last five trading days and 17.06% for the last 4 weeks. Vertex Pharmaceuticals Incorporated is up 13.68% in the last 3-month period. Year-to-Date the stock performance stands at 17.06%. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rose 0.43% or 0.37 points on Wednesday and made its way into the gainers of the day. After trading began at $85.98 the stock was seen hitting $86.43 as a peak level and $84.33 as the lowest level. The stock ended up at $86.24. The daily volume was measured at 1,754,741 shares. The 52-week high of the share price is $103.73 and the 52-week low is $71.46. The company has a market cap of $21,390 million.
Company has reported several Insider transactions to the SEC, on Jan 13, 2017, Joshua S Boger (director) sold 8,000 shares at 83.15 per share price.On Nov 17, 2016, Amit Sachdev (EVP, Policy, Access & Value) sold 116 shares at 93.36 per share price.On Nov 17, 2016, Paul M Silva (SVP & Corp Controller) sold 1 shares at 94.14 per share price.
Vertex Pharmaceuticals Incorporated Last issued its quarterly earnings results on Jan 25, 2017. The company reported $0.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $0.29.Analysts expectations of $ 452.50.During the same quarter in the previous year, the company posted $0.17 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Vertex Pharmaceuticals Incorporated was Reiterated by Stifel on Jan 26, 2017 to Buy, Lowers Price Target to $ 100 from a previous price target of $108 .Vertex Pharmaceuticals Incorporated was Initiated by Oppenheimer to Perform on Dec 15, 2016.
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)